Page 4 - B Biontech News Today

Maryland officials said Wednesday they expect about a third of children ages 5 to 11 to get vaccinated against COVID-19 in the next three to four weeks, following federal approval Tuesday night of Pfizer-BioNTech's shots.

President Biden said Wednesday that COVID-19 vaccines for school-aged kids will be widely available across the U.S. by next week, latching onto the "giant step forward" in the pandemic fight in the wake of a bruising Election Day for Democrats.

President Biden said Wednesday that COVID-19 vaccines for school-aged kids will be widely available across the U.S. by next week, latching onto the "giant step forward" in the pandemic fight in the wake of a bruising Election Day for Democrats.

U.S. regulators are delaying their decision on Moderna's COVID-19 vaccine for 12- to 17-year-olds while they study the rare risk of heart inflammation, the company said Sunday.

The Food and Drug Administration on Friday authorized the Pfizer-BioNTech COVID-19 vaccine for emergency use in children ages 5 to 11, a major step in making the shots available to school-aged kids by early November.

The Food and Drug Administration on Friday authorized the Pfizer-BioNTech COVID-19 vaccine for emergency use in children ages 5 to 11, a major step in making the shots available to school-aged kids by early November.

Fewer than a third of parents plan to vaccinate their children for COVID-19 "right away" once the shots become available to 5- to 11-year-olds, according to a poll released Thursday.

Fewer than a third of parents plan to vaccinate their children for COVID-19 "right away" once the shots become available to 5- to 11-year-olds, according to a poll released Thursday.

A key advisory panel on Tuesday recommended the Pfizer-BioNTech COVID-19 shots for emergency use in children ages 5 to 11, setting the stage for shots to become available to 28 million children by early November and fueling debate over the risks and rewards of vaccinating an age group that's accounted for 0.01% of COVID-19 deaths in America.

A key advisory panel on Tuesday recommended the Pfizer-BioNTech COVID-19 shots for emergency use in children ages 5 to 11, setting the stage for shots to become available to 28 million children by early November and fueling debate over the risks and rewards of vaccinating an age group that's accounted for 0.01% of COVID-19 deaths in America.